Topics:
Gastrointestinal Cancers • Medical Oncology
How do you approach adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma?
In light of the results of the ESPAC-4 trial, is combination gemcitabine plus capecitabine being considered over single agent gemcitabine for adjuvant therapy?
http://meetinglibrary.asco.org/content/162546-176
Answer from: Medical Oncologist at Academic Institution
For my good performance status patients, I offer gem/cap as per the ESPAC-4 trial. Though the incremental benefit is modest, it was statistically significant and the toxicities associated with the combination are quite manageable most of the time. I look forward to the results of three other adjuvan...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
For resected pancreas cancer - the ESPAC-4 data for gemcitabine/capecitabine support the use of this regimen and outside of a trial setting, this combination represents a new standard option for this disease. We now routinely use this regimen in practice. Nonetheless given pending data on other mult...
Answer from: Medical Oncologist at Academic Institution
The main take away from PRODIGE24 further support the role for adjuvant chemotherapy with an added benefit for FOLFIRINOX. For good performance status patients, I would recommend FOLFIRINOX chemotherapy, which showed a significant improvement in disease free survival and overall survival compared t...
Comments
Medical Oncologist at Florida Cancer Specialists and Research Institute
@Daniel H. Ahn, could you provide us insight since...
@Daniel H. Ahn, could you provide us insight since...
Medical Oncologist at Mayo Clinic
@Muhammad H. Imam, good question. There are variou...
@Muhammad H. Imam, good question. There are variou...